A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B
Phase 1
Completed
- Conditions
- Hyperlipidemias
- Interventions
- Drug: AD-221Drug: AD-221A and AD-221B
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05202405
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A
Phase 3
Completed
- Conditions
- Primary Hypercholesterolemia
- Interventions
- Drug: AD-221ADrug: AD-221Drug: AD-221BDrug: AD-221C
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT05131997
- Locations
- 🇰🇷
Yonsei University Hospital, Seoul, Seodaemun-gu, Korea, Republic of
A Study to Compare Pharmacokinetic Parameters and Safety Profiles Between AD-109 and AD-1091
Phase 1
Completed
- Conditions
- Embolism and Thrombosis
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05128591
- Locations
- 🇰🇷
H+ Yangji Hospital, Seoul, Korea, Republic of
A Study to Compare PK, PD and Safety of the AD-214 and AD-2141
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05062876
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of AD-208
Phase 3
Completed
- Conditions
- Androgenetic Alopecia
- Interventions
- Drug: placebo of AD-208Drug: AD-208Drug: AD-2081Drug: placebo of AD-2081
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT04825561
- Locations
- 🇰🇷
The Catholic University of Korea, Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of
A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132
Phase 1
Completed
- Conditions
- Gastroesophagus Reflux Disease
- Interventions
- Drug: AD-213-BDrug: AD-2132
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04755985
- Locations
- 🇰🇷
Young-Ran Yoon, Daegu, Korea, Republic of
A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131
Phase 1
Completed
- Conditions
- Gastroesophagus Reflux Disease
- Interventions
- Drug: AD-213-ADrug: AD-2131
- First Posted Date
- 2020-12-31
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04690868
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
A Study to Compare PK, PD and Safety of the AD-214-02 and Rabeprazole
Phase 1
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: AD-214-02Drug: Rabeprazole
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT04622358
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Evaluating the Pharmacokinetic Interaction Between AD-2101 and AD-2102
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- Drug: AD-2101Drug: AD-2102Drug: AD-2101 + AD-2102
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04600284
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole
Phase 1
Completed
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Addpharma Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04494243
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath